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A BS TR AC T
BACKGROUND
The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intra-
venous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 
6 months, but the benefits wane over time.
METHODS
We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neo-
nates with symptomatic congenital CMV disease, comparing 6 months of therapy with 
6 weeks of therapy. The primary end point was the change in hearing in the better ear 
(“best-ear” hearing) from baseline to 6 months. Secondary end points included the 
change in hearing from baseline to follow-up at 12 and 24 months and neurodevel-
opmental outcomes, with each end point adjusted for central nervous system in-
volvement at baseline.
RESULTS
A total of 96 neonates underwent randomization, of whom 86 had follow-up data at 
6 months that could be evaluated. Best-ear hearing at 6 months was similar in the 
6-month group and the 6-week group (2 and 3 participants, respectively, had im-
provement; 36 and 37 had no change; and 5 and 3 had worsening; P = 0.41). Total-
ear hearing (hearing in one or both ears that could be evaluated) was more likely to 
be improved or to remain normal at 12 months in the 6-month group than in the 
6-week group (73% vs. 57%, P = 0.01). The benefit in total-ear hearing was maintained 
at 24 months (77% vs. 64%, P = 0.04). At 24 months, the 6-month group, as compared 
with the 6-week group, had better neurodevelopmental scores on the Bayley Scales of 
Infant and Toddler Development, third edition, on the language-composite compo-
nent (P = 0.004) and on the receptive-communication scale (P = 0.003). Grade 3 or 4 
neutropenia occurred in 19% of the participants during the first 6 weeks. During the 
next 4.5 months of the study, grade 3 or 4 neutropenia occurred in 21% of the partici-
pants in the 6-month group and in 27% of those in the 6-week group (P = 0.64).
CONCLUSIONS
Treating symptomatic congenital CMV disease with valganciclovir for 6 months, as 
compared with 6 weeks, did not improve hearing in the short term but appeared to 
improve hearing and developmental outcomes modestly in the longer term. (Funded 
by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, 
NCT00466817.)
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Congenital cytomegalovirus (CMV) infection is the leading nongenetic cause of sensorineural hearing loss1-4 and is the 
most frequent known viral cause of mental retar-
dation5; the infection affects 0.6 to 0.7% of live 
births in industrialized countries.6-8 A total of 
10% of congenitally infected neonates have symp-
tomatic disease at birth, of whom 35% have 
sensorineural hearing loss, up to two thirds have 
neurologic deficits, and 4% die during the new-
born period.7-11 Although congenital CMV infec-
tion is rare overall, it accounts for 21% of chil-
dren with hearing loss at birth and 24% of those 
with hearing loss at 4 years of age.1,12
The National Institute of Allergy and Infec-
tious Diseases (NIAID) Collaborative Antiviral 
Study Group (CASG) found that among neonates 
with symptomatic congenital CMV disease involv-
ing the central nervous system (CNS), ganciclovir 
administered intravenously over a period of 
6 weeks was associated with improved audio-
logic outcomes at 6 months of life, but there was 
suggestion that this benefit could wane over the 
first 2 years of life.13 Treated infants had fewer 
developmental delays, according to Denver Devel-
opmental evaluations, than untreated infants.14 
In a follow-up study, the CASG determined the 
dose of oral valganciclovir (the prodrug of gan-
ciclovir) that results in systemic exposure to 
ganciclovir that is similar to that with intrave-
nous ganciclovir.15 Therapy with intravenous 
ganciclovir or oral valganciclovir for 6 weeks is 
now an accepted treatment option for patients 
with symptomatic congenital CMV disease involv-
ing the CNS.16
Me thods
STUDY DESIGN AND POPULATION
Neonates with symptomatic congenital CMV dis-
ease, with or without CNS involvement, were eli-
gible for enrollment. Given the rarity of this dis-
ease, 40 study sites participated, and each was 
anticipated to contribute only a few study par-
ticipants. All the study participants had CMV de-
tected in urine or throat-swab specimens by means 
of culture, shell-vial culture, or polymerase-chain-
reaction assay. Symptomatic disease was defined 
as one or more of the following: thrombocytope-
nia, petechiae, hepatomegaly, splenomegaly, in-
trauterine growth restriction, hepatitis, or CNS 
involvement such as microcephaly, intracranial 
calcifications, abnormal cerebrospinal fluid in-
dexes, chorioretinitis, sensorineural hearing loss, 
or the detection of CMV DNA in cerebrospinal 
fluid. Eligible participants had a gestational age 
of 32 weeks or more, were 30 days of age or less, 
and weighed at least 1800 g at the initiation of 
therapy.
The institutional review board at each study 
center approved the study protocol. After written 
informed consent was obtained from the parent 
or legal guardian, all participants received val-
ganciclovir (at a dose of 16 mg per kilogram of 
body weight, orally twice daily) for 6 weeks.15 
Participants then underwent randomization in a 
1:1 ratio to receive either continued valganciclo-
vir or placebo for 4.5 months. The dose of the 
study medication was adjusted monthly for 
growth. Study drugs (oral valganciclovir and 
placebo) were provided by Hoffmann–La Roche, 
which had no role in the study design or data 
analyses or in the writing of the manuscript or 
the decision to submit it for publication. Study 
personnel and the participants’ families were 
unaware of the randomization assignments.
The primary end point prespecified in the 
protocol was the change in hearing in the better 
ear (“best-ear” hearing), from baseline to the 
6-month follow-up.13 Secondary end points pre-
specified in the protocol included the change in 
total-ear hearing (i.e., hearing in one or both 
ears that could be evaluated) from baseline to 
follow-up at 6, 12, and 24 months; change in 
best-ear hearing from baseline to follow-up at 
12 and 24 months; neurologic impairment at 12 
and 24 months; and adverse events leading to the 
permanent discontinuation of therapy. Tertiary 
end points included the correlation of viral load 
in whole blood with audiologic and neurodevelop-
mental outcomes, adverse events related to the 
study medication, and characterization of blood 
concentrations of ganciclovir.
AUDIOLOGIC ASSESSMENTS
Brain-stem auditory evoked response was assessed 
at entry, and assessment of brain-stem auditory 
evoked response or visual-reinforcement audi-
ometry was performed at 6, 12, and 24 months. 
Hearing thresholds were defined as follows: 0 to 
20 dB for normal hearing, 21 to 45 dB for mild 
hearing loss, 46 to 70 dB for moderate hearing 
loss, and 71 dB or higher for severe hearing 
loss.3,10,13
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An independent audiologist, who was unaware 
of the randomization assignments, reviewed all 
the audiometry reports and classified, according 
to hearing thresholds, all ears that could be 
evaluated, giving “total ear” classifications. The 
study audiologist then assigned the “best ear” 
classification for the participant at that study 
visit. For example, if a participant had mild 
hearing loss in the left ear and severe hearing 
loss in the right ear, the best-ear classification 
was mild hearing loss. Odd numbers of total 
ears according to treatment category are reported 
because a patient may have had only one ear that 
could be evaluated (e.g., if the patient had otitis 
media in one ear, such that the ear could not be 
evaluated, and a normal, second ear that could 
be evaluated).
OTHER ASSESSMENTS
The Bayley Scales of Infant and Toddler Develop-
ment, third edition (Bayley-III), was administered 
at 12 and 24 months by a neuropsychologist at 
each study site who was unaware of the random-
ization assignments.17 Whole blood for the eval-
uation of CMV viral load18 was obtained at base-
line, weekly for 4 weeks, every 2 weeks for 
8 weeks, and monthly for 4 months.
White-cell count, white-cell differential count, 
measurement of hemoglobin level, platelet count, 
and aspartate aminotransferase, alanine amino-
transferase, total bilirubin, and creatinine mea-
surements were performed serially. Assessments 
regarding toxic effects were quantified with the 
use of the NIAID Division of AIDS Toxicity 
Tables.19
STATISTICAL ANALYSIS
The primary objective was to assess the difference 
between the 6-week group and 6-month group in 
the change in best-ear hearing from baseline to 
6 months of age. The Wilcoxon–Mann–Whitney 
test was used for analysis of the primary end 
point; linear models were used for analysis of 
secondary end points with adjustment for covari-
ates. We calculated that a sample of 37 partici-
pants per group would provide the study with 
85% power to detect an effect size of 0.169 from 
the null value of 0.5. We assumed that 15% of 
participants would not be eligible for randomiza-
tion at 6 weeks and that another 10% would not 
complete the hearing evaluation at 6 months; 
therefore, we determined that the original sam-
ple should be 94 participants. During the course 
of the study, the data and safety monitoring 
board suggested that, owing to inadequate base-
line or 6-month data, the sample size should be 
increased to achieve the targeted 37 participants 
per group. The sample was increased to 104 par-
ticipants to accommodate 10% of the partici-
pants with outcomes that could not be evaluated 
owing to inadequate hearing data at baseline or 
6 months. A 5% overenrollment was allowed for 
operational purposes.
The modified intention-to-treat population in-
cluded participants who underwent randomiza-
tion and received at least one dose of blinded 
treatment. The prespecified statistical analysis 
plan dictated that efficacy outcomes be adjusted 
for CNS involvement. For the secondary audio-
logic end points, hearing results were analyzed 
on the basis of two sets of binary outcomes: 
first, improved hearing or maintenance of normal 
hearing from baseline to follow-up, as compared 
with worsened hearing or maintenance of the 
same degree of hearing loss from baseline to 
follow-up; and second, worsened hearing from 
baseline to follow-up, as compared with improved 
hearing, maintenance of normal hearing, or 
maintenance of the same degree of hearing loss 
from baseline to follow-up (see the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org, for additional details).
Any hearing assessments completed after 
cochlear implantation were excluded, as were 
missing hearing assessments and those that 
were not able to be evaluated. P values of less 
than 0.05 for hearing outcomes and less than 
0.0071 for neurodevelopmental outcomes were 
considered to indicate statistical significance. 
For full details of the study conduct and analy-
ses, see the protocol (including the statistical 
analysis plan), available at NEJM.org.
R esult s
DEMOGRAPHIC CHARACTERISTICS  
OF THE PARTICIPANTS
From June 2008 through May 2011, we enrolled 
109 participants at 31 study sites. A total of 96 
participants were randomly assigned to receive 
blinded study medication after receiving 6 weeks 
of valganciclovir; 47 participants were assigned 
to continue receiving the active drug (the 6-month 
group), and 49 were assigned to receive placebo 
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(the 6-week group) (Fig. 1 and Table 1). Of the 96 
participants, 9 (6 participants in the 6-month 
group, and 3 in the 6-week group) stopped tak-
ing the blinded drug before completing 6 months 
of the study. No participant discontinued the 
study drug owing to adverse events.
AUDIOLOGIC OUTCOMES
Primary End Point
Among 43 participants in the 6-month group 
who had assessments that could be evaluated 
at 6 months, the change in best-ear hearing from 
baseline to 6 months indicated improvement in 
2 participants, no change in 36, and worsened 
hearing in 5. Similarly, among 43 participants in 
the 6-week group, 3 had improved hearing, 37 had 
unchanged hearing, and 3 had worsened hearing 
(P = 0.41 by the Wilcoxon–Mann–Whitney test).
Secondary End Points
In the binary assessment, the change in best-ear 
hearing from baseline to 6 months was similar 
in the two treatment groups (P = 0.24, after ad-
justment for baseline CNS involvement) (Table 2). 
The between-group difference in the change in 
best-ear hearing from baseline to 12 months and 
from baseline to 24 months approached signifi-
cance after adjustment for baseline CNS involve-
ment (P = 0.05 and P = 0.07, respectively) (Table 2).
In the assessment of total-ear hearing, partici-
pants who received 6 months of valganciclovir 
were more likely than those who received 6 weeks 
of therapy to have improved hearing or to have 
maintained normal hearing between baseline and 
12 months, after adjustment for CNS involve-
ment at baseline (73% vs. 57%; odds ratio, 3.04; 
95% confidence interval [CI], 1.26 to 7.35; 
P = 0.01) (Table 2). Similar results were evident 
when prematurity and age at the initiation of 
treatment were added to the model (P = 0.01). 
96 Entered blinded phase of study, were
included in modified intention-to-treat
population, and underwent randomization
109 Were enrolled
13 Did not enter blinded
phase of study
283 Patients were screened
174 Were not enrolled
47 Were assigned to receive
valganciclovir beginning day 42
49 Were assigned to receive
placebo beginning day 42
43 Had baseline and 6-mo
hearing assessments
that could be evaluated
43 Had baseline and 6-mo
hearing assessments
that could be evaluated
41  Had baseline and 12-mo 
hearing assessments that 
could be evaluated
43 Had ≥1 components of
Bayley-III at 12 mo
40 Had baseline and 12-mo 
hearing assessments that 
could be evaluated
45 Had ≥1 components of
Bayley-III at 12 mo
37 Had baseline and 24-mo 
hearing assessments that 
could be evaluated
42 Had ≥1 components of
Bayley-III at 24 mo
31 Had baseline and 24-mo 
hearing assessments that 
could be evaluated
41 Had ≥1 components of
Bayley-III at 24 mo
Figure 1. Randomization and Follow-up of the Study 
Participants.
The participants who had hearing and developmental 
 assessments that could be evaluated at 12 and 24 months 
of follow-up did not necessarily constitute subgroups 
of the preceding groups with follow-up assessments. At 
6 months, 4 participants in the 6-month group could 
not be evaluated because of loss to follow-up (2 par-
ticipants) and incomplete audiologic data (2), and 6 in 
the 6-week group could not be evaluated because of 
loss to follow-up (2), incomplete audiologic data (3), 
and follow-up assessment that was not performed dur-
ing the study window (1). At 12 months, 6 participants 
in the 6-month group could not be evaluated because 
of cochlear implantation (1 participant), loss to follow-
up (3), and incomplete audiologic data (2), and 9 in the 
6-week group could not be evaluated because of cochlear 
implantation (3), loss to follow-up (1), incomplete audi-
ologic data (3), and follow-up assessment that was not 
performed during the study window (2). At 24 months, 
10 participants in the 6-month group could not be eval-
uated because of cochlear implantation (4 participants), 
loss to follow-up (4), and concurrent otitis media (2), 
and 18 in the 6-week group could not be evaluated be-
cause of cochlear implantation (6), loss to follow-up 
(5), incomplete audiologic data (3), follow-up assess-
ment that was not performed during the study window 
(3), and concurrent otitis media (1). Neurodevelop-
mental outcomes were assessed with the use of the 
Bayley Scales of Infant and Toddler Development, third 
edition (Bayley-III).
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Among the 53 participants with baseline CNS 
involvement, the rate ratio for improved or pro-
tected (i.e., maintenance of normal) total-ear 
hearing at 12 months in the 6-month group, as 
compared with the 6-week group, was 1.66 (95% 
CI, 0.92 to 2.40), and the rate-ratio difference was 
0.27 (95% CI, 0.09 to 0.45); for the 28 participants 
without baseline CNS involvement, the rate ratio 
was 1.22 (95% CI, 0.99 to 1.45), and rate-ratio 
difference was 0.16 (95% CI, 0.03 to 0.29).
The benefit of longer-term therapy in the total-
ears analysis was maintained at 24 months, with 
improved outcomes after adjustment for CNS 
involvement at baseline (77% in the 6-month 
group vs. 64% in the 6-week group; odds ratio, 
2.61; 95% CI, 1.05 to 6.43; P = 0.04) (Table 2). 
Similar results were evident when prematurity 
and age at the initiation of treatment were added 
to the model (P = 0.04). The rate ratio for im-
proved or protected total-ear hearing at 24 months 
among the 42 participants with baseline CNS 
involvement in the 6-month group, as compared 
with the 6-week group, was 1.46 (95% CI, 0.87 
to 2.05), and the rate-ratio difference was 0.23 
(95% CI, 0.05 to 0.41); among the 26 participants 
without baseline CNS involvement, the rate ratio 
was 1.19 (95% CI, 0.98 to 1.40), and the rate-
ratio difference was 0.14 (95% CI, 0.01 to 0.27). 
The timing of initiation of valganciclovir within 
the first month of life (e.g., <3 weeks of age vs. 
3 to 4 weeks of age) did not correlate with au-
diologic outcomes at 12 months or at 24 months 
(P>0.23 for both comparisons).
NEURODEVELOPMENTAL OUTCOMES
In the analysis adjusted for CNS involvement at 
baseline, participants randomly assigned to re-
ceive 6 months of valganciclovir, as compared 
with those randomly assigned to 6 weeks of treat-
ment, had higher Bayley-III language-composite 
scores at 24 months (P = 0.005) and higher recep-
tive-communication scale scores at 24 months 
(P = 0.003). No significant interaction effects were 
found when outcome and CNS involvement at 
baseline were incorporated in a single model, in-
dicating that the treatment benefits were similar 
in the group with CNS involvement and the group 
without CNS involvement. The differences be-
tween the 6-month group and the 6-week group 
with respect to Bayley-III scores were maintained 
when age at the initiation of treatment and pre-
maturity were added to the model (P = 0.004 and 
P = 0.003, respectively) (Table 3). All the other 
components of the Bayley-III assessments trend-
ed toward improved outcomes among partici-
pants in the 6-month group, as compared with 
those in the 6-week group.
Table 1. Characteristics of the Participants at Baseline.*
Characteristic
6 Mo  
of Therapy
(N = 47)
6 Wk  
of Therapy
(N = 49)
P  
Value
Gestational age — no. (%) 0.68
32 to ≤37 wk 24 (51) 22 (45)
>37 wk 23 (49) 27 (55)
Age at enrollment — no. (%) 0.08
<7 days 6 (13) 7 (14)
7–14 days 19 (40) 12 (24)
15–21 days 10 (21) 6 (12)
22–29 days 12 (26) 24 (49)
Extent of CMV disease — no. (%)†
Thrombocytopenia 38 (81) 34 (69) 0.24
Petechiae 22 (47) 20 (41) 0.68
Hepatomegaly 26 (55) 21 (43) 0.31
Splenomegaly 23 (49) 22 (45) 0.84
Intrauterine growth restriction 17 (36) 22 (45) 0.41
Hepatitis 21 (45) 25 (51) 0.55
Central nervous system involvement 34 (72) 29 (59) 0.20
Microcephaly — no. (%) 14 (30) 17 (35) 0.19
Chorioretinitis — no. (%) 2 (4) 1 (2) 1.00
Neuroimaging results —  
no./total no. (%)‡
0.62
Normal 9/45 (20) 12/47 (26)
Abnormal 36/45 (80) 35/47 (74)
Baseline BSER of the best ear in participants 
with 6-mo follow-up data — no./
total no. (%)§
0.17
Normal 32/43 (74) 25/43 (58)
Mild 5/43 (12) 8/43 (19)
Moderate 3/43 (7) 2/43 (5)
Severe 3/43 (7) 8/43 (19)
* Table S1 in the Supplementary Appendix provides a full tabulation of the demo-
graphic and clinical characteristics at baseline.
† Participants could have multiple manifestations of cytomegalovirus (CMV) dis-
ease. Hepatitis was defined by an elevated aminotransferase or bilirubin level.
‡ Neuroimaging was performed with the use of magnetic resonance imaging, 
computed tomography, or ultrasonography of the head.
§ Hearing thresholds were assessed with the use of brain-stem auditory evoked 
response (BSER) and were defined as follows: a threshold of 0 to 20 dB for 
normal hearing, 21 to 45 dB for mild hearing loss, 46 to 70 dB for moderate 
hearing loss, and 71 dB or higher for severe hearing loss.
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VIROLOGIC RESULTS
Viral loads in whole blood decreased in parallel 
in the two study groups during the first 6 weeks 
of open-label valganciclovir therapy and then di-
verged after randomization (Fig. 2). In the analy-
sis that was adjusted for an interaction effect 
between treatment and the area under the curve 
(AUC) of the viral load, lower viral loads, as com-
pared with higher viral loads, correlated with 
better hearing outcomes at 6, 12, and 24 months 
among participants in the 6-month group (P<0.01 
for all comparisons) but not among those in the 
Table 3. Treatment Effects on Neurologic Outcomes According to Study Group.*
Bayley-III Component† 12-Mo Follow-up 24-Mo Follow-up
6-Mo Group 6-Wk Group P Value 6-Mo Group 6-Wk Group P Value
Cognitive composite 0.01 0.02
No. of participants 43 45 42 41
Mean 89.6±3.0 79.5±2.8 84.4±2.6 76.0±2.6
Range 55–115 9.5–120 55–135 55–110
Language composite  0.009  0.004
No. of participants 41 43 41 41
Mean 87.6±3.0 76.8±2.9 84.6±2.9 72.5±2.9
Range 47–118 11–112 47–121 47–103
Receptive-communication scale 0.05  0.003
No. of participants 41 43 41 41
Mean 7.5±0.5 6.1±0.5 7.3±0.5 5.2±0.5
Range 1–14 1–12 1–14 1–10
Expressive-communication scale 0.02 0.02
No. of participants 41 44 41 41
Mean 8.0±0.5 6.5±0.5 7.3±0.5 5.5±0.5
Range 1–13 1–13 1–13 1–11
Motor composite 0.03 0.01
No. of participants 42 44 41 40
Mean 82.6±3.2 73.2±3.0 85.5±3.3 74.1±3.2
Range 46–112 11–112 46–121 46–121
Fine-motor scale 0.11 0.06
No. of participants 41 44 42 40
Mean 7.3±0.6 6.0±0.6 8.0±0.6 6.4±0.6
Range 1–11 0.1–13 1–15 1–19
Gross-motor scale 0.07 0.02
No. of participants 42 44 42 40
Mean 6.7±0.5 5.4±0.5 7.0±0.5 5.3±0.5
Range 1–14 0.1–15 1–13 1–12
* Plus–minus values are means ±SE. Data were adjusted for central nervous system involvement at baseline, prematurity, 
and age at the initiation of treatment. A P value of less than 0.0071 (i.e., 0.05 divided by 7) was considered to indicate 
statistical significance, with the use of Bonferroni adjustment for multiple testing. Ranges represent the minimum and 
maximum values of the raw data.
† All the composite scores on the Bayley Scales of Infant and Toddler Development, third edition (Bayley-III), range from 
40 to 160, with higher scores indicating better developmental outcomes. All the scale scores on the Bayley-III range 
from 1 to 19, with higher scores indicating better developmental outcomes. Decimal points in the ranges reflect the 
specific raw data in the scales for at least one study participant, as captured on the case-report form and verified during 
the on-site monitoring visits.
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6-week group (P>0.68 for all comparisons). There 
was no correlation between the AUC of the viral 
load and neurodevelopmental outcomes beyond 
that provided by treatment.
SAFETY ASSESSMENTS
Of the 109 participants, 21 (19%) had grade 3 or 
4 neutropenia during the first 6 weeks of open-
label valganciclovir therapy. From week 6 through 
month 6, a total of 10 of the 47 participants (21%) 
who received the active drug had grade 3 or 
4 neutropenia, as compared with 13 of 49 (27%) 
who received placebo (P = 0.64). A total of 3 par-
ticipants had the drug temporarily suspended 
because of an absolute neutrophil count of less 
than 500 per cubic millimeter. All treatment in-
terruptions occurred within the first 6 weeks of 
the study, and treatment was resumed after reso-
lution of the neutropenia.
The alanine aminotransferase and aspartate 
aminotransferase levels increased slightly at 
months 4 and 5 in the group of participants who 
received the active drug, although the differ-
ences between this group and the group that 
received placebo were not statistically significant 
(P>0.59 for both aminotransferase comparisons) 
or clinically significant (all mean values, <90 U 
per liter). No deaths occurred. There were no 
significant differences in the rate of adverse 
events between the two study groups.
Discussion
We believe that only one randomized, controlled 
trial of antiviral treatment for symptomatic con-
genital CMV disease has been conducted previ-
ously, also by the NIAID CASG.13 Other reports 
in the literature involve individual cases20-24 or 
small, uncontrolled case series.25-27 The earlier 
randomized, controlled trial showed a benefit of 
6 weeks of parenteral ganciclovir therapy with re-
spect to best-ear hearing from baseline to 6 months, 
but there was a suggestion that this benefit 
wanes over the first 2 years of life.13 On the 
basis of these data, the change in best-ear hear-
ing from baseline to 6 months was selected as 
the primary end point of this trial. This selection 
positioned the current study to extend our knowl-
edge of the effect of antiviral therapy on hearing 
and allowed for sample-size assessments in the 
development of the study protocol.
We also selected numerous clinically relevant 
secondary end points before the initiation of the 
study to explore the effect of longer-term anti-
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Figure 2. Cytomegalovirus DNA Viral Load in Whole Blood in Participants Receiving the Study Therapy.
Participants with a viral load of less than 100 were assessed as having a viral load of 10 (i.e., 1.0 in the graph). P values 
are for the between-group comparisons at the respective time points.
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viral treatment on longer-term hearing improve-
ment. These included the change in best-ear hear-
ing and the change in total-ear hearing from 
baseline to 12 months and from baseline to 24 
months in order to more completely ascertain 
the effect of antiviral treatment on short-term (to 
6 months of age) and longer-term (to 2 years of 
age) time frames. Formal neurodevelopmental 
outcomes were incorporated as secondary end 
points in the study to assess the effect of anti-
viral treatment on neurodevelopmental outcome.
We did not find significant between-group 
differences in the primary study end point of 
change in best-ear hearing between baseline and 
6 months. The change in total-ear hearing be-
tween baseline and 6 months also was similar in 
the two groups. However, the secondary study 
end points of change in total-ear hearing be-
tween baseline and 12 months and between base-
line and 24 months differed significantly be-
tween the two groups, with participants receiving 
6 months of therapy, as compared with those 
receiving 6 weeks of treatment, having im-
proved hearing outcomes. Data from our pre-
specified secondary end points suggest that the 
6-month regimen of antiviral treatment modestly 
improves hearing outcomes in the long term but 
does not provide an additional benefit with re-
spect to short-term outcomes over that provided 
by 6 weeks of treatment.
The magnitude of the long-term benefit can 
be viewed in several ways. The calculation of odds 
ratios showed that, as compared with patients 
who received shorter therapy, patients who re-
ceived longer therapy had 3.0 times the odds of 
having improved hearing or protection of nor-
mal hearing at 12 months and 2.6 times the 
odds at 24 months. The calculation of the rate 
ratio showed that among participants with CNS 
involvement at baseline, those in the 6-month 
group had a 65% greater likelihood of having 
better outcomes from baseline to 12 months than 
those in the 6-week group and a 46% greater 
likelihood of having better outcomes from base-
line to 24 months than those in the 6-week 
group. Among participants without CNS involve-
ment, the corresponding values were 22% and 
19%. Rate-ratio differences between the groups 
range from 0.14 to 0.27, depending on the pres-
ence of CNS involvement at baseline and on the 
follow-up interval. We caution that spurious find-
ings may have arisen from the multiple statisti-
cal tests conducted for the secondary hearing 
end points considered in this report.
With respect to neurodevelopmental outcomes, 
we found that the communicative end points of 
scores on the language-composite component 
and the receptive-communication scale of the 
Bayley-III17 assessment, with Bonferroni adjust-
ment for multiple testing, were improved with 
the longer treatment, with low average results 
among participants treated for 6 months but 
borderline results among participants treated for 
6 weeks (see the Supplementary Appendix for 
scoring definitions), after adjustment for factors 
that could affect development. All the scores on 
the other components of the Bayley-III were also 
higher in the 6-month treatment group than in 
the 6-week group (Table 3), although the differ-
ences were not significant. No significant inter-
action effects were found, indicating similar 
neurologic treatment benefits regardless of CNS 
involvement.
The rates of grade 3 or 4 neutropenia during 
the first 6 weeks of treatment were lower among 
the participants in the current study who received 
oral valganciclovir (19% of participants) than 
among participants in previous CASG studies 
who received intravenous ganciclovir for 6 weeks 
(63%)13 or intravenous ganciclovir for 2 weeks 
and oral valganciclovir for 4 weeks (38%),15 per-
haps owing to the higher maximum concentra-
tion of the drug associated with intravenous 
versus oral drug delivery. From week 6 to month 
7 in the current trial, the incidence of grade 3 or 
4 neutropenia was similar among participants 
randomly assigned to continue valganciclovir 
and those randomly assigned to receive placebo 
(21% and 27%, respectively; P = 0.64). Thus, drug-
induced neutropenia is of primary concern dur-
ing the first 6 weeks of treatment, and the risk 
appears to be reduced when treatment is solely 
with oral valganciclovir.13 Ganciclovir has toxic 
effects on the gonads and is carcinogenic in ani-
mal models,28 and although these toxic effects 
have not been seen in humans, the information 
should be conveyed to families of neonates for 
whom valganciclovir therapy is being considered.
The data from this controlled study suggest 
that among infants with symptomatic congeni-
tal CMV disease, 6 months of oral valganciclovir 
therapy has a moderately favorable effect on long-
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term audiologic and neurodevelopmental out-
comes, after adjustment for baseline CNS involve-
ment; in addition, this regimen was not associated 
with an excess risk of neutropenia and avoided 
the need to maintain intravenous access for pro-
longed periods of time. These data do not apply 
to infants with asymptomatic congenital CMV 
infection, since there are no controlled studies 
showing a benefit in this population and the 
possibility of harm exists. Since CMV-associated 
sensorineural hearing loss fluctuates over time 
in more than one third of patients as part of the 
natural history of this disease, prospective, con-
trolled trial designs are critical to assess treat-
ment benefit in patients with congenital CMV 
infections.
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